ADHD Treatment Pemoline Too Risky to Sell, FDA Says

Drug Industry Daily
KEYWORDS FDA
A A

The FDA has concluded that attention-deficit/hyperactivity disorder (ADHD) drug pemoline is too dangerous to market because it poses serious liver toxicity risks.

To View This Article:

Login

Subscribe To Drug Industry Daily